Tokyo Tape
Sign in
← CellSeed

Annual report

7776.TEDINET S100XUKD
Period2025-01-01 → 2025-12-31
Filed2026-03-26
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed
Key figures · 85
MetricValuePeriodScopeSource row
Revenue¥84m2025-01-01 → 2025-12-31StandaloneNet sales
Revenue¥193m2024-01-01 → 2024-12-31StandaloneNet sales
Revenue¥190m2023-01-01 → 2023-12-31vStandaloneNet sales (5-year summary)
Revenue¥126m2022-01-01 → 2022-12-31vStandaloneNet sales (5-year summary)
Revenue¥162m2021-01-01 → 2021-12-31dStandaloneNet sales (5-year summary)
Operating income−¥1.0bn2025-01-01 → 2025-12-31StandaloneOperating income
Operating income−¥846m2024-01-01 → 2024-12-31StandaloneOperating income
Ordinary income−¥1.1bn2025-01-01 → 2025-12-31StandaloneOrdinary income
Ordinary income−¥848m2024-01-01 → 2024-12-31StandaloneOrdinary income
Ordinary income−¥710m2023-01-01 → 2023-12-31vStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥754m2022-01-01 → 2022-12-31vStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥887m2021-01-01 → 2021-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥866m2021-01-01 → 2021-12-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax−¥1.1bn2025-01-01 → 2025-12-31StandaloneIncome before income taxes
Profit before tax−¥858m2024-01-01 → 2024-12-31StandaloneIncome before income taxes
Net income (owners)−¥915m2021-01-01 → 2021-12-31dStandaloneProfit loss attributable to owners of parent (5-year summary)
Net income−¥1.1bn2025-01-01 → 2025-12-31StandaloneProfit loss
Net income−¥860m2024-01-01 → 2024-12-31StandaloneProfit loss
Net income−¥847m2023-01-01 → 2023-12-31vStandaloneNet income loss (5-year summary)
Net income−¥760m2022-01-01 → 2022-12-31vStandaloneNet income loss (5-year summary)
Net income−¥913m2021-01-01 → 2021-12-31dStandaloneNet income loss (5-year summary)
Total assets¥1.7bnat 2025-12-31StandaloneAssets
Total assets¥2.4bnat 2024-12-31StandaloneAssets
Total assets¥2.5bnat 2023-12-31vStandaloneTotal assets (5-year summary)
Total assets¥1.5bnat 2022-12-31vStandaloneTotal assets (5-year summary)
Total assets¥1.4bnat 2021-12-31dStandaloneTotal assets (5-year summary)
Total assets¥1.4bnat 2021-12-31dStandaloneTotal assets (5-year summary)
Total liabilities¥387mat 2025-12-31StandaloneLiabilities
Total liabilities¥270mat 2024-12-31StandaloneLiabilities
Net assets / equity¥1.3bnat 2025-12-31StandaloneNet assets
Net assets / equity¥2.2bnat 2024-12-31StandaloneNet assets
Net assets / equity¥2.2bnat 2023-12-31vStandaloneNet assets
Net assets / equity¥1.2bnat 2022-12-31vStandaloneNet assets (5-year summary)
Net assets / equity¥1.0bnat 2021-12-31dStandaloneNet assets (5-year summary)
Net assets / equity¥1.0bnat 2021-12-31dStandaloneNet assets (5-year summary)
Cash and deposits¥1.3bnat 2025-12-31StandaloneCash and deposits
Cash and deposits¥2.1bnat 2024-12-31StandaloneCash and deposits
Cash & equivalents¥1.3bnat 2025-12-31StandaloneCash and cash equivalents
Cash & equivalents¥2.1bnat 2024-12-31StandaloneCash and cash equivalents
Cash & equivalents¥2.2bnat 2023-12-31vStandaloneCash and cash equivalents
Cash & equivalents¥1.1bnat 2022-12-31vStandaloneCash and cash equivalents (5-year summary)
Cash & equivalents¥931mat 2021-12-31dStandaloneCash and cash equivalents (5-year summary)
Operating cash flow−¥989m2025-01-01 → 2025-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥866m2024-01-01 → 2024-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥779m2023-01-01 → 2023-12-31vStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥718m2022-01-01 → 2022-12-31vStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥817m2021-01-01 → 2021-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Investing cash flow−¥27m2025-01-01 → 2025-12-31StandaloneNet cash provided by used in investment activities
Investing cash flow−¥18m2024-01-01 → 2024-12-31StandaloneNet cash provided by used in investment activities
Investing cash flow¥56m2023-01-01 → 2023-12-31vStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow¥62m2022-01-01 → 2022-12-31vStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥110m2021-01-01 → 2021-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Financing cash flow¥200m2025-01-01 → 2025-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow¥855m2024-01-01 → 2024-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow¥1.8bn2023-01-01 → 2023-12-31vStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥882m2022-01-01 → 2022-12-31vStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥397m2021-01-01 → 2021-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
EPS (basic)¥-31.822025-01-01 → 2025-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-25.722024-01-01 → 2024-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-29.432023-01-01 → 2023-12-31vStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-36.312022-01-01 → 2022-12-31vStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-53.182021-01-01 → 2021-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-53.082021-01-01 → 2021-12-31dStandaloneBasic earnings loss per share (5-year summary)
Net assets per share¥35.37at 2025-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥62.1at 2024-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥68.08at 2023-12-31vStandaloneNet assets per share (5-year summary)
Net assets per share¥47.26at 2022-12-31vStandaloneNet assets per share (5-year summary)
Net assets per share¥56.44at 2021-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥57.43at 2021-12-31dStandaloneNet assets per share (5-year summary)
Equity ratio76.0%at 2025-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio88.5%at 2024-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio86.9%at 2023-12-31vStandaloneEquity to asset ratio (5-year summary)
Equity ratio74.8%at 2022-12-31vStandaloneEquity to asset ratio (5-year summary)
Equity ratio72.0%at 2021-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio72.4%at 2021-12-31dStandaloneEquity to asset ratio (5-year summary)
Shares issued35,557,719at 2025-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued34,666,419at 2024-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued31,459,019at 2023-12-31vStandaloneTotal number of issued shares (5-year summary)
Shares issued24,422,619at 2022-12-31vStandaloneTotal number of issued shares (5-year summary)
Shares issued17,759,419at 2021-12-31dStandaloneTotal number of issued shares (5-year summary)
Employees36at 2025-12-31StandaloneNumber of employees
Employees38at 2024-12-31StandaloneNumber of employees
Employees35at 2023-12-31vStandaloneNumber of employees
Employees30at 2022-12-31vStandaloneNumber of employees
Employees44at 2021-12-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 37
SegmentItemPeriodValue
Reconciling Itemsreconcilingcapex2025-01-01 → 2025-12-31¥229,000
Reconciling Itemsreconcilingsegment assetsat 2025-12-31¥1.4bn
Reconciling Itemsreconcilingsegment profit2025-01-01 → 2025-12-31−¥218m
Cell Sheet Regenerative Medicinereportable segmentcapex2025-01-01 → 2025-12-31¥488,000
Cell Sheet Regenerative Medicinereportable segmentemployeesat 2025-12-3120 pure
Cell Sheet Regenerative Medicinereportable segmentrevenue2025-01-01 → 2025-12-31¥2m
Cell Sheet Regenerative Medicinereportable segmentrevenue external2025-01-01 → 2025-12-31¥2m
Cell Sheet Regenerative Medicinereportable segmentsegment assetsat 2025-12-31¥96m
Cell Sheet Regenerative Medicinereportable segmentsegment profit2025-01-01 → 2025-12-31−¥723m
Laboratory Consumables And Equipmentreportable segmentcapex2025-01-01 → 2025-12-31¥52m
Laboratory Consumables And Equipmentreportable segmentemployeesat 2025-12-3111 pure
Laboratory Consumables And Equipmentreportable segmentrevenue2025-01-01 → 2025-12-31¥82m
Laboratory Consumables And Equipmentreportable segmentrevenue external2025-01-01 → 2025-12-31¥82m
Laboratory Consumables And Equipmentreportable segmentsegment assetsat 2025-12-31¥112m
Laboratory Consumables And Equipmentreportable segmentsegment profit2025-01-01 → 2025-12-31−¥105m
—segment totalcapex2025-01-01 → 2025-12-31¥52m
—segment totalrevenue2025-01-01 → 2025-12-31¥84m
—segment totalrevenue external2025-01-01 → 2025-12-31¥84m
—segment totalsegment assetsat 2025-12-31¥208m
—segment totalsegment profit2025-01-01 → 2025-12-31−¥828m
Reconciling Itemsreconcilingcapex2024-01-01 → 2024-12-31¥16m
Reconciling Itemsreconcilingsegment assetsat 2024-12-31¥2.2bn
Reconciling Itemsreconcilingsegment profit2024-01-01 → 2024-12-31−¥230m
Cell Sheet Regenerative Medicinereportable segmentrevenue2024-01-01 → 2024-12-31¥1m
Cell Sheet Regenerative Medicinereportable segmentrevenue external2024-01-01 → 2024-12-31¥1m
Cell Sheet Regenerative Medicinereportable segmentsegment assetsat 2024-12-31¥70m
Cell Sheet Regenerative Medicinereportable segmentsegment profit2024-01-01 → 2024-12-31−¥596m
Laboratory Consumables And Equipmentreportable segmentcapex2024-01-01 → 2024-12-31¥2m
Laboratory Consumables And Equipmentreportable segmentrevenue2024-01-01 → 2024-12-31¥192m
Laboratory Consumables And Equipmentreportable segmentrevenue external2024-01-01 → 2024-12-31¥192m
Laboratory Consumables And Equipmentreportable segmentsegment assetsat 2024-12-31¥121m
Laboratory Consumables And Equipmentreportable segmentsegment profit2024-01-01 → 2024-12-31−¥21m
—segment totalcapex2024-01-01 → 2024-12-31¥2m
—segment totalrevenue2024-01-01 → 2024-12-31¥193m
—segment totalrevenue external2024-01-01 → 2024-12-31¥193m
—segment totalsegment assetsat 2024-12-31¥191m
—segment totalsegment profit2024-01-01 → 2024-12-31−¥616m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 989
ItemContextValueUnit
LiabilitiesCurrentYearInstant_NonConsolidatedMember_ReportableSegmentsMember209347000JPY
LiabilitiesCurrentYearInstant_NonConsolidatedMember_ReconcilingItemsMember178112000JPY
LiabilitiesCurrentYearInstant_NonConsolidatedMember387459000JPY
Depreciation segment informationCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E24158-000LaboratoryConsumablesAndEquipmentReportableSegmentsMember－JPY
Depreciation segment informationCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E24158-000CellSheetRegenerativeMedicineReportableSegmentsMember－JPY
Depreciation segment informationCurrentYearDuration_NonConsolidatedMember_ReportableSegmentsMember－JPY
Depreciation segment informationCurrentYearDuration_NonConsolidatedMember_ReconcilingItemsMember－JPY
Depreciation segment informationCurrentYearDuration_NonConsolidatedMember－JPY
Increase in property plant and equipment and intangible assetsCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E24158-000LaboratoryConsumablesAndEquipmentReportableSegmentsMember52000000JPY
Increase in property plant and equipment and intangible assetsCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E24158-000CellSheetRegenerativeMedicineReportableSegmentsMember488000JPY
Increase in property plant and equipment and intangible assetsCurrentYearDuration_NonConsolidatedMember_ReportableSegmentsMember52488000JPY
Increase in property plant and equipment and intangible assetsCurrentYearDuration_NonConsolidatedMember_ReconcilingItemsMember229000JPY
Increase in property plant and equipment and intangible assetsCurrentYearDuration_NonConsolidatedMember52717000JPY
Impairment loss elPrior1YearDuration_NonConsolidatedMember_jpcrp030000-asr_E24158-000LaboratoryConsumablesAndEquipmentReportableSegmentsMember2320000JPY
Impairment loss elPrior1YearDuration_NonConsolidatedMember_jpcrp030000-asr_E24158-000CellSheetRegenerativeMedicineReportableSegmentsMember－JPY
Impairment loss elPrior1YearDuration_NonConsolidatedMember_UnallocatedAmountsAndEliminationMember16046000JPY
Impairment loss elPrior1YearDuration_NonConsolidatedMember18367000JPY
Impairment loss elCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E24158-000LaboratoryConsumablesAndEquipmentReportableSegmentsMember52000000JPY
Impairment loss elCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E24158-000CellSheetRegenerativeMedicineReportableSegmentsMember488000JPY
Impairment loss elCurrentYearDuration_NonConsolidatedMember_UnallocatedAmountsAndEliminationMember229000JPY
Impairment loss elCurrentYearDuration_NonConsolidatedMember52717000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)有価証券報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2026-03-26
Fiscal year cover pageFilingDateInstant
Original text (Japanese)第25期（自　2025年１月１日　至　2025年12月31日）
Company name cover pageFilingDateInstant
Original text (Japanese)株式会社セルシード
Company name in english cover pageFilingDateInstantCellSeed Inc.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長　橋本　せつ子
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)東京都江東区青海二丁目５番10号テレコムセンタービル
Telephone number address of registered headquarter cover pageFilingDateInstant03-6380-7490
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)取締役　経営管理部門長　中岡　圭一郎
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)東京都江東区青海二丁目５番10号テレコムセンタービル
Telephone number nearest place of contact cover pageFilingDateInstant03-6380-7490
Name of contact person nearest place of contact cover pageFilingDateInstant
Original text (Japanese)取締役　経営管理部門長　中岡　圭一郎
Place for public inspection cover page (text)FilingDateInstantText · Plus
Edinet codeFilingDateInstantE24158
Fund codeFilingDateInstant－
Security codeFilingDateInstant77760
Filer name in japaneseFilingDateInstant
Original text (Japanese)株式会社セルシード
Filer name in englishFilingDateInstantCellSeed Inc.
Fund name in japaneseFilingDateInstant－
Fund name in englishFilingDateInstant－
Cabinet office ordinanceFilingDateInstant
Original text (Japanese)企業内容等の開示に関する内閣府令
Document typeFilingDateInstant
Original text (Japanese)第三号様式
Accounting standardsFilingDateInstantJapan GAAP
Whether consolidated financial statements are preparedFilingDateInstantfalse
Industry code when consolidated financial statements are prepared in accordance with industry specific regulationsFilingDateInstant－
Industry code when financial statements are prepared in accordance with industry specific regulationsFilingDateInstantCTE
Current fiscal year start dateFilingDateInstant2025-01-01

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 13 of 13 passed
balance sheet identitynon_consolidated 2024-12-31pass
balance sheet identitynon_consolidated 2025-12-31pass
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2023-12-31pass
statement vs summary · net assetsnon_consolidated 2024-12-31pass
statement vs summary · net assetsnon_consolidated 2025-12-31pass
statement vs summary · operating cash flownon_consolidated 2024-01-01/2024-12-31pass
statement vs summary · operating cash flownon_consolidated 2025-01-01/2025-12-31pass
statement vs summary · revenuenon_consolidated 2024-01-01/2024-12-31pass
statement vs summary · revenuenon_consolidated 2025-01-01/2025-12-31pass
statement vs summary · total assetsnon_consolidated 2024-12-31pass
statement vs summary · total assetsnon_consolidated 2025-12-31pass